Skip to main page content

• HOME
• Current Issue
• Archive
• Alerts
• About ASM
• Contact us
• Tech Support
• Journals.ASM.org

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bébéar, C. M. Articles by Bébéar, C. Search for Related Content PubMed PubMed Citation Articles by Bébéar, C. M. Articles by Bébéar, C.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, October 2003, p. 3323-3325, Vol. 47, No. 10
0066-4804/03/$08.00+0     DOI: 10.1128/AAC.47.10.3323-3325.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.

DNA Gyrase and Topoisomerase IV Mutations in Clinical Isolates of Ureaplasma spp. and Mycoplasma hominis Resistant to Fluoroquinolones

C. M. Bébéar,^* H. Renaudin, A. Charron, M. Clerc, S. Pereyre, and C. Bébéar

Laboratoire de Bactériologie, Université Victor Segalen Bordeaux 2, 33076 Bordeaux, France

Received 27 March 2003/ Returned for modification 6 May 2003/ Accepted 3 July 2003

Top Abstract Text References

 
Twelve clinical isolates of Ureaplasma spp. and one isolate of Mycoplasma hominis were examined for resistance to fluoroquinolones. Previously described mutations at positions 83 and 95 in GyrA (Escherichia coli numbering) and positions 80 and 87 in ParC were found. Unusual alterations were described at positions ParC 123 and 134.

Top Abstract Text References

 
Ureaplasma urealyticum and Mycoplasma hominis are commonly isolated from the lower urogenital tract of healthy adults but could be responsible for genital and extragenital infections (7). The species U. urealyticum has been recently divided into two new species, namely, Ureaplasma parvum (previously U. urealyticum biovar 1) and U. urealyticum (previously U. urealyticum biovar 2) (10, 12). In this study, they will be considered together as Ureaplasma spp.

Fluoroquinolones interact in bacteria with the type II topoisomerases DNA gyrase and topoisomerase IV, both of which are composed of two A and two B subunits; these subunits are encoded by the gyrA and gyrB genes for DNA gyrase and by the parC and parE genes for topoisomerase IV (8). We recently reported in vitro and in vivo fluoroquinolone-resistant mutants of M. hominis associated with alterations in GyrA, ParC, and ParE quinolone resistance-determining regions (QRDRs) (4, 6). The Ureaplasma spp. quinolone-resistant clinical isolates identified during this study have been characterized for their species identification and subtyping and for their QRDR status in regard to their fluoroquinolone susceptibility. Furthermore, we describe also a new clinical isolate of M. hominis that is highly resistant to fluoroquinolones.

Growth conditions and antibiotic susceptibility testing of the Ureaplasma and M. hominis strains have been previously described (14). The Ureaplasma sp. reference strains, the serovar 3 standard (ATCC 27815) designated as the type strain of U. parvum, and the serovar 8 standard (ATCC 27618) designated as the type strain of U. urealyticum (12), as well as the clinical isolates, were grown in Shepard medium. Thirteen clinical isolates comprising UUb to UUg5 (Table 1), which were obtained at the Pellegrin Hospital in Bordeaux, and UUa, which was isolated at the Hospital of Montpellier, France, all of which were grown in our laboratory between 1989 and 1999, were studied. The M. hominis reference strain PG21 (ATCC 23114) and the clinical isolate MHe obtained at the Foch Hospital in Suresnes, France, were grown in Hayflick modified medium.

View this table: [in this window] [in a new window]

TABLE 1. Sources of the 13 clinical Ureaplasma isolates

PCR was carried out with 1 µM each primer and 5 µl of template DNA for the Ureaplasma species identification and subtyping (10) and for the QRDR amplification of the four topoisomerase genes for Ureaplasma spp. and M. hominis, as described elsewhere (4, 5). PCR products were directly sequenced by using an ABI PRISM dRhodamine terminator cycle sequencing ready reaction kit (Applied Biosystems).

Thirteen clinical isolates of Ureaplasma spp. from seven patients were examined; their origin is described in Table 1. The first one, UUa, was previously reported (2, 5). Among the 1,224 Ureaplasma spp. strains isolated in our laboratory between 1989 and 1999, 37 isolates were classified as resistant to ofloxacin by the susceptibility testing kit Mycoplasma SIR (Bio-Rad). Determining the ofloxacin MICs for these 37 isolates led us to study 11 strains for which the ofloxacin MIC is 4 µg/ml, namely, UUb to UUd and UUe2 to UUg5 (Table 1). We report here also a new clinical isolate of M. hominis, named MHe, isolated from a knee synovial fluid of a male patient with hypogammaglobulinemia and a lung transplant. He received at least one regimen of ofloxacin.

We investigated our Ureaplasma isolates for species identification and subtyping using the algorithm recently described by Kong et al. (10). Thus, isolates UUe1 and UUe2, isolated from the same patient, were identified as U. parvum (biovar 1). The other isolates belonged to the species U. urealyticum (biovar 2), subtype 1 or subtype 2. It is tempting to speculate that the paired isolates (UUe1 and UUe2, from the same patient) and the seven isolates from the sexual partners (UUf1-2 from the male, and UUg1-5 from the female) are from the same clonal origin. Furthermore, among the strains resistant to fluoroquinolones, we isolated more U. urealyticum (from six patients) than U. parvum (from one patient), which is not the case commonly. Indeed, U. parvum clinical isolates usually outnumber U. urealyticum clinical isolates (1, 10). There is a probable bias in our study, with nine isolates being possibly from the same clonal origin and with the number of patients studied being statistically too small to be conclusive.

The 13 ureaplasmal clinical strains were characterized for their susceptibilities to eight fluoroquinolones and for the QRDR status of their gyrA, gyrB, parC, and parE genes (Table 2). Except the fluoroquinolone-susceptible isolate UUe1, all other isolates had a high-level resistance to the older fluoroquinolones, such as norfloxacin, pefloxacin, ofloxacin, and ciprofloxacin, with MICs ranging from 4 to >128 µg/ml. Susceptibility to the newer fluoroquinolones, like sparfloxacin, levofloxacin, moxifloxacin, and gemifloxacin, depends on the resistant isolate, but increases in MICs were much less pronounced except for mutant UUa. Thus, the MICs of these fluoroquinolones varied between 0.25 and 16 µg/ml.

View this table: [in this window] [in a new window]

TABLE 2. Characteristics of 13 Ureaplasma sp. and one M. hominis clinical isolates

The 12 quinolone-resistant isolates were found to carry target mutations in either parC (one isolate) or gyrA and parC (11 isolates). No mutation was detected in the gyrB or parE QRDR (Table 2). Except isolate UUe2, all other resistant isolates presented two alterations in ParC, namely, the Ala125(123)-to-Thr and Ala136(134)-to-Thr changes (Escherichia coli numbering). Our data did not allow an assessment of the contribution of these two mutations to the observed resistance phenotype. However, these positions are located close to the Tyr122(120) active site of the protein, and several mutations in this area have been frequently described for other quinolone-resistant bacteria (3, 9), but most of these mutations could not be clearly related to resistance to fluoroquinolones. All other alterations found in this study (Table 2) have been already described for other bacteria concerning either the altered position or the amino acid change. The hot spots ParC Ser83(80) and Glu87(84) and GyrA Gln100(83) have been found previously to be mutated in numerous other bacteria and in mycoplasmas (4, 6, 11). The GyrA Asp112-to-Glu alteration, which is rare and which is homologous to position GyrA 95 in E. coli, has been found to be mutated in Streptococcus pneumoniae (13) without a clear direct link to quinolone resistance. Furthermore, in vitro studies with laboratory mutants would be helpful to determine the preferential target of fluoroquinolones in ureaplasmas. Some isolates, like UUb and UUf1 or UUd and UUf1, which had the same amino acid changes in the QRDR of GyrA and ParC, harbored fourfold differences in MICs of ciprofloxacin or pefloxacin, respectively. Other undefined resistance mutations seem likely to be present in some of the strains studied.

The drug susceptibility profile and the QRDR status of the M. hominis isolate are summarized in Table 2. Compared to the reference strain PG21, isolate MHe harbored a high level cross-resistance to the eight fluoroquinolones tested, with the lowest MIC being that of gemifloxacin at 2 µg/ml. This resistance in an immunodeficiency context, which was found also for the previously described clinical strains of quinolone-resistant M. hominis (6), was associated with four target alterations (Table 2): GyrA 83, ParC 80 and 134, and ParE 462.

In summary, this is the first extensive description of fluoroquinolone resistance in clinical isolates of Ureaplasma spp. In our laboratory during a 10-year period, we found 12 Ureaplasma spp. isolates resistant to fluoroquinolones. The clinical histories of patients showed one or several quinolone regimens before the appearance of resistant bacteria and a correlation with immunosuppression. These findings confirm the necessity to monitor the antibiotic susceptibility of urogenital mycoplasmas isolated in humans and to control it routinely in immunocompromised patients.

 
We thank P. Honderlick (Laboratoire de Microbiologie, Hôpital Foch, Suresnes, France) for the gift of strain MHe.

 
* Corresponding author. Mailing address: Laboratoire de Bactériologie, Université Victor Segalen Bordeaux 2, 146 rue Léo Saignat, 33076 Bordeaux Cedex, France. Phone: (33) 5.57.57.16.25. Fax: (33) 5.56.93.29.40. E-mail: cecile.bebear{at}u-bordeaux2.fr.

Top Abstract Text References

 

1
1. Abele-Horn, M., C. Wolff, P. Dressel, F. Pfaff, and A. Zimmermann. 1997. Association of Ureaplasma urealyticum biovars with clinical outcome for neonates, obstetric patients, and gynecological patients with pelvic inflammatory disease. J. Clin. Microbiol. 35:1199-1202.[Abstract]
2
2. Abraham, B., C. Leclercq, C. Bébéar, H. Renaudin, and F. Janbon. 2001. Septic arthritis due to Ureaplasma urealyticum: concerning one case. Med. Mal. Infect. 31:453-454.
3
3. Bast, D. J., D. E. Low, C. L. Duncan, L. Kilburn, L. A. Mandell, R. J. Davidson, and J. C. S. Deazavedo. 2000. Fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae: contributions of type II topoisomerase mutations and efflux to levels of resistance. Antimicrob. Agents Chemother. 44:3049-3054.[Abstract/Free Full Text]
4
4. Bébéar, C. M., H. Renaudin, A. Charron, J. M. Bové, C. Bébéar, and J. Renaudin. 1998. Alterations in topoisomerase IV and DNA gyrase in quinolone-resistant mutants of Mycoplasma hominis obtained in vitro. Antimicrob. Agents Chemother. 42:2304-2311.[Abstract/Free Full Text]
5
5. Bébéar, C. M., H. Renaudin, A. Charron, D. Gruson, M. Lefrançois, and C. Bébéar. 2000. In vitro activity of trovafloxacin compared to those of five antimicrobials against Mycoplasma hominis and Ureaplasma urealyticum fluoroquinolone-resistant isolates that have been genetically characterized. Antimicrob. Agents Chemother. 44:2557-2560.[Abstract/Free Full Text]
6
6. Bébéar, C. M., J. Renaudin, A. Charron, H. Renaudin, B. de Barbeyrac, T. Schaeverbeke, and C. Bébéar. 1999. Mutations in the gyrA, parC, and parE genes associated with fluoroquinolone resistance in clinical isolates of Mycoplasma hominis. Antimicrob. Agents Chemother. 43:954-956.[Abstract/Free Full Text]
7
7. Blanchard, A., and C. M. Bébéar. 2002. Mycoplasmas of humans, p. 45-71. In S. Razin and R. Herrmann (ed.), Molecular biology and pathogenicity of mycoplasmas. Kluwer Academic/Plenum Publishers, London, United Kingdom.
8
8. Hooper, D. C. 1998. Bacterial topoisomerases, anti-topoisomerases, and anti-topoisomerase resistance. Clin. Infect. Dis. 27:S54-S63.
9
9. Ince, D., and D. C. Hooper. 2000. Mechanisms and frequency of resistance to premafloxacin in Staphylococcus aureus: novel mutations suggest novel drug-target interactions. Antimicrob. Agents Chemother. 44:3344-3350.[Abstract/Free Full Text]
10
10. Kong, F. R., Z. F. Ma, G. James, S. Gordon, and G. L. Gilbert. 2000. Species identification and subtyping of Ureaplasma parvum and Ureaplasma urealyticum using PCR-based assays. J. Clin. Microbiol. 38:1175-1179.[Abstract/Free Full Text]
11
11. Reinhardt, A. K., C. M. Bébéar, M. Kobisch, I. Kempf, and A. V. Gautier-Bouchardon. 2002. Characterization of mutations in DNA gyrase and topoisomerase IV involved in quinolone resistance of Mycoplasma gallisepticum mutants obtained in vitro. Antimicrob. Agents Chemother. 46:590-593.[Abstract/Free Full Text]
12
12. Robertson, J. A., G. W. Stemke, J. W. Davis, R. Harasawa, D. Thirkell, F. R. Kong, M. C. Shepard, and D. K. Ford. 2002. Proposal of Ureaplasma parvum sp. nov. and emended description of Ureaplasma urealyticum (Shepard et al. 1974) Robertson et al. 2001. Int. J. Syst. Evol. Microbiol. 52(Part 2):587-597.[Abstract]
13
13. Taba, H., and N. Kusano. 1998. Sparfloxacin resistance in clinical isolates of Streptococcus pneumoniae: involvement of multiple mutations in gyrA and parC genes. Antimicrob. Agents Chemother. 42:2193-2196.[Abstract/Free Full Text]
14
14. Waites, K. B., C. M. Bébéar, J. A. Robertson, D. F. Talkington, and G. E. Kenny (ed.). 2001. Cumitech 34: laboratory diagnosis of mycoplasmal infections. American Society for Microbiology, Washington, D.C.

---

Antimicrobial Agents and Chemotherapy, October 2003, p. 3323-3325, Vol. 47, No. 10
0066-4804/03/$08.00+0     DOI: 10.1128/AAC.47.10.3323-3325.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.

This article has been cited by other articles:

• Lysnyansky, I., Mikula, I., Gerchman, I., Levisohn, S. (2009). Rapid Detection of a Point Mutation in the parC Gene Associated with Decreased Susceptibility to Fluoroquinolones in Mycoplasma bovis. Antimicrob. Agents Chemother. 53: 4911-4914 [Abstract] [Full Text]  
• Beeton, M. L., Chalker, V. J., Kotecha, S., Spiller, O. B. (2009). Comparison of full gyrA, gyrB, parC and parE gene sequences between all Ureaplasma parvum and Ureaplasma urealyticum serovars to separate true fluoroquinolone antibiotic resistance mutations from non-resistance polymorphism. J Antimicrob Chemother 64: 529-538 [Abstract] [Full Text]  
• Beeton, M. L., Chalker, V. J., Maxwell, N. C., Kotecha, S., Spiller, O. B. (2009). Concurrent Titration and Determination of Antibiotic Resistance in Ureaplasma Species with Identification of Novel Point Mutations in Genes Associated with Resistance. Antimicrob. Agents Chemother. 53: 2020-2027 [Abstract] [Full Text]  
• Geissdorfer, W., Sandner, G., John, S., Gessner, A., Schoerner, C., Schroppel, K. (2008). Ureaplasma urealyticum Meningitis in an Adult Patient. J. Clin. Microbiol. 46: 1141-1143 [Abstract] [Full Text]  
• Duffy, L., Glass, J., Hall, G., Avery, R., Rackley, R., Peterson, S., Waites, K. (2006). Fluoroquinolone Resistance in Ureaplasma parvum in the United States. J. Clin. Microbiol. 44: 1590-1591 [Abstract] [Full Text]  
• Gruson, D., Pereyre, S., Renaudin, H., Charron, A., Bebear, C., Bebear, C. M. (2005). In Vitro Development of Resistance to Six and Four Fluoroquinolones in Mycoplasma pneumoniae and Mycoplasma hominis, Respectively. Antimicrob. Agents Chemother. 49: 1190-1193 [Abstract] [Full Text]  
• Ahmed, A. M, Miyoshi, S.-i., Shinoda, S., Shimamoto, T. (2005). Molecular characterization of a multidrug-resistant strain of enteroinvasive Escherichia coli O164 isolated in Japan. J Med Microbiol 54: 273-278 [Abstract] [Full Text]  
• Pereyre, S., Renaudin, H., Bebear, C., Bebear, C. M. (2004). In Vitro Activities of the Newer Quinolones Garenoxacin, Gatifloxacin, and Gemifloxacin against Human Mycoplasmas. Antimicrob. Agents Chemother. 48: 3165-3168 [Abstract] [Full Text]  

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bébéar, C. M. Articles by Bébéar, C. Search for Related Content PubMed PubMed Citation Articles by Bébéar, C. M. Articles by Bébéar, C.